Stay updated with the latest stem-cell-therapy news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on stem-cell-therapy topics.
Stempeutics will have to meet certain regulatory milestones, he said, as the product would be made in India and sent to Japan In a first of sorts in stem cell therapy, India's Stempeutics has inked an "option licence agreement" with Japan's Medinet, a listed company focussed on regenerative medicine - to take the former's product used in treating chronic limb threatening ischemia (CLTI), to Japan. Japan is a tough regulatory market, BN Manohar, Stempeutics Chief Executive Officer told business ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.